CJC-1295 Dosage Guide: How Much, How Often, and Common Mistakes

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

Most people who quit CJC-1295 do it during titration, and most of those quits trace to dosing decisions. Get the schedule right and the rest is much easier.

Standard Dosing Schedule for CJC-1295

Not FDA-approved. No officially established human dosing.

The typical schedule for CJC-1295 is varies; once weekly (DAC) or daily (no-DAC) in user protocols via subcutaneous injection (research use). Half-life of approximately 6-8 days (DAC version); ~30 minutes (no-DAC version) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for CJC-1295 holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of CJC-1295 is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in CJC-1295 side effects and the cost angle of dose escalation in CJC-1295 cost.

What the Trials Used

Published trial data for CJC-1295 comes primarily from: Teichman et al. 2006, JCEM — early human pharmacokinetic and pharmacodynamic data on CJC-1295 DAC.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For CJC-1295: the standard contraindications for this drug class apply.

Bottom Line

Dosing CJC-1295 is a long game. Get the titration right, hold steady, and adjust deliberately based on how your body responds.

Frequently Asked Questions

Related Reading

• CJC-1295 101: A Plain-English Guide for 2026
• CJC-1295 Side Effects: The Complete List and How to Handle Them
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.